1. Home
  2. CMPS vs AVLN Comparison

CMPS vs AVLN Comparison

Compare CMPS & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo COMPASS Pathways Plc American Depository Shares

CMPS

COMPASS Pathways Plc American Depository Shares

HOLD

Current Price

$11.28

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc. Common Stock

SELL

Current Price

$24.42

Market Cap

1.3B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CMPS
AVLN
Founded
2020
2011
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
2020
2026

Fundamental Metrics

Financial Performance
Metric
CMPS
AVLN
Price
$11.28
$24.42
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
16
5
Target Price
$23.75
★ $61.80
AVG Volume (30 Days)
★ 2.4M
294.8K
Earning Date
11-03-2026
11-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.88
$24.14
52 Week High
$15.87
$40.17

Technical Indicators

Market Signals
Indicator
CMPS
AVLN
Relative Strength Index (RSI) 34.33 28.77
Support Level $10.66 N/A
Resistance Level $14.74 $30.45
Average True Range (ATR) 0.57 1.61
MACD -0.16 -0.25
Stochastic Oscillator 6.05 6.98

Price Performance

Historical Comparison
CMPS
AVLN

About CMPS COMPASS Pathways Plc American Depository Shares

Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.

About AVLN Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

Share on Social Networks: